Poor long-term outcomes for cryptococcal meningitis in rural South Africa

South African Medical Journal

Volumn 101, Issue 4, 2011, Pages 251-252

  Lessells, Richard J ^a   Mutevedzi, Portia C ^a   Heller, Tom ^b   Newell, Marie Louise ^a,c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Hlabisa Hospital   (South Africa)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; FLUCONAZOLE;

ADULT; ARTICLE; CONSCIOUSNESS DISORDER; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIMARY HEALTH CARE; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; RISK FACTOR; RURAL AREA; SOUTH AFRICA; TREATMENT OUTCOME; VOMITING;

EID: 79955936580     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/samj.4378     Document Type: Article

References (16)

1. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis 2010;10:67.
2. Sloan DJ, Dedicoat MJ, Lalloo DG. Treatment of cryptococcal meningitis in resource limited settings. Curr Opin Infect Dis 2009;22(5):455-463.
3. Houlihan CF, Bland RM, Mutevedzi PC, et al. Cohort profile: Hlabisa HIV Treatment and Care Programme. Int J Epidemiol 2010; 12 Feb. [Epub ahead of print].
4. Kisenge PR, Hawkins AT, Maro VP, et al. Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect Dis 2007;7:39.
5. Lightowler JV, Cooke GS, Mutevedzi P, Lessells RJ, Newell ML, Dedicoat M. Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa. PLoS One 2010;5(1):e8630.
6. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007;45(1):76-80.
7. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008;47(1):123-130.
8. Bisson GP, Nthobatsong R, Thakur R, et al. The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr 2008;49(2):227-229.
9. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008;46(11):1694-1701.
10. Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIVassociated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008;47(12):1556-1561.
11. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010;50(11):1532-1538.
12. Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009;49(5):702-709.
13. Govender N, Cohen C, Meiring S, et al. Trends in treatment of adults with incident cryptococcosis, South Africa, 2005-2008. San Fransisco, California: 17th Conference on Retroviruses and Opportunistic Infections, 2010.
14. Collett G, Parrish A. Fluconazole donation and outcomes assessment in cryptococcal meningitis. S Afr Med J 2007;97(3):175-176.
15. Jarvis JN, Meintjes G, Williams Z, Rebe K, Harrison TS. Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. S Afr Med J 2010;100(6):378-382.
16. Jarvis JN, Boulle A, Loyse A, et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS 2009;23(9):1182-1183.